Is Datopotamab used to treat triple-negative breast cancer?

Datopotomab Deruxtecan, referred to as Dato-DXd) is an antibody-drug conjugate (ADC) that targets the TROP2 protein. Its therapeutic effect in a variety of solid tumors is currently being studied in multiple clinical trials, especially triple-negative breast cancer (TNBC). TROP2 is a protein highly expressed in a variety of epithelial tumors. The expression level is also very high in TNBC, thus providing a clear target basis for Datopotamab.

In clinical trials such as TROPION-PanTumor01 and TROPION-Breast01, Datopotamab demonstrated promising anti-tumor activity in the treatment of metastatic or advanced TNBC patients. Studies have shown that its objective response rate (ORR) can reach more than 30%, and the median progression-free survival (PFS) is close to 4.4 months. Some patients even achieve longer disease control. This makes Datopotamab considered an important drug candidate in the future targeted treatment of TNBC.

Although currentlyDatopotamab has not been officially approved for the treatment of triple-negative breast cancer globally, multiple phase III clinical trials are ongoing, including combinations with chemotherapy drugs and immunotherapy. If these research results confirm its efficacy and safety, Datopotamab is expected to be used as a standard regimen in the treatment of triple-negative breast cancer in the future, especially for patients who have poor response to traditional chemotherapy.

Overall,Datopotamab's prospects in the treatment of triple-negative breast cancer are widely optimistic, but it is still in the clinical trial stage and has not yet received formal approval from regulatory agencies. For eligible patients, it is recommended to pay attention to relevant clinical trials under the guidance of doctors as an exploratory option other than standard treatment, while paying close attention to its subsequent research and marketing progress.

Reference materials:https://www.drugs.com/